https://www.selleckchem.com/pr....oducts/Temsirolimus.
https://www.selleckchem.com/pr....oducts/Temsirolimus.
[Survival analysis regarding silicosis sufferers in Wuxi City]. 79% (4/29), respectively. The DCRs were 59.18% (29/49) and 55.17% (16/29), and m-PFS was 7.82 ± 6.90 and 6.03 ± 4.50 months, respectively. Regarding adverse events (AEs), apatinib was associated with a higher incidence of hair hypopigmentation and pneumothorax, while anlotinib was associated with a higher incidence of pharyngalgia or hoarseness. Conclusion Both apatinib and anlotinib were effective for the tr
Like
Comment
Share
